arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2407.11054cs.LGcs.AI
收藏

生成式AI用于卫生技术评估:机遇、挑战与政策考量

Generative AI for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations

National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health(美国国立卫生研究院国家生物医学成像与生物工程研究所);University of Florida(佛罗里达大学);University of Florida Health(佛罗里达大学健康科学中心);Tulane University School of Public Health and Tropical Medicine(杜兰大学公共卫生与热带医学学院);Intelligent Medical Objects(智能医疗对象公司);Yale University(耶鲁大学);National Institute for Health and Care Excellence(英国国家卫生与临床优化研究所);Cairo University(开罗大学);ISPOR - The Professional Society for Health Economics and Outcomes Research(国际药物经济学与结果研究学会);Massachusetts General Hospital(麻省总医院);Harvard Medical School(哈佛医学院);Harvard University(哈佛大学)

Rachael Fleurence, Jiang Bian, Xiaoyan Wang, Hua Xu, Dalia Dawoud, Mitch Higashi, Jagpreet Chhatwal

AI总结:

本综述探讨了生成式AI与基础模型在卫生技术评估(HTA)的证据综合、生成、临床试验及经济建模四大领域的应用潜力,分析了其局限性与伦理风险,并为HTA机构负责任地整合该技术提出了政策建议。

摘要:

本综述介绍了生成式人工智能(AI)和基础模型(包括大型语言模型,LLMs)对卫生技术评估(HTA)的变革潜力。我们探讨了它们在四个关键领域的应用:证据综合、证据生成、临床试验和经济建模:(1)证据综合:生成式AI有潜力通过提出搜索词、筛选摘要和提取数据并以显著的准确性来协助自动化文献综述和荟萃分析;(2)证据生成:这些模型有可能促进自动化处理和分析日益增多的大规模真实世界数据(RWD)集合,包括非结构化临床笔记和影像,从而提升真实世界证据(RWE)生成的速度与质量;(3)临床试验:生成式AI可用于优化试验设计、改善患者匹配,并更高效地管理试验数据;(4)经济建模:生成式AI还能辅助卫生经济模型的开发,从概念化到验证,从而简化整体HTA流程。尽管前景广阔,但这些技术虽在快速进步,仍处于初期阶段,需要对其在HTA中的应用持续进行谨慎评估。为确保其负责任的使用与实施,结合这些工具的研究的开发者和使用者都应熟悉其当前的局限性,包括与科学有效性、偏倚风险相关的问题,并考量公平性与伦理影响。我们还调研了当前的政策环境,并为HTA机构负责任地将生成式AI整合至其工作流程中提供建议,强调了人类监督的重要性及这些工具快速演变的本质。

英文摘要:

This review introduces the transformative potential of generative Artificial Intelligence (AI) and foundation models, including large language models (LLMs), for health technology assessment (HTA). We explore their applications in four critical areas, evidence synthesis, evidence generation, clinical trials and economic modeling: (1) Evidence synthesis: Generative AI has the potential to assist in automating literature reviews and meta-analyses by proposing search terms, screening abstracts, and extracting data with notable accuracy; (2) Evidence generation: These models can potentially facilitate automating the process and analyze the increasingly available large collections of real-world data (RWD), including unstructured clinical notes and imaging, enhancing the speed and quality of real-world evidence (RWE) generation; (3) Clinical trials: Generative AI can be used to optimize trial design, improve patient matching, and manage trial data more efficiently; and (4) Economic modeling: Generative AI can also aid in the development of health economic models, from conceptualization to validation, thus streamlining the overall HTA process. Despite their promise, these technologies, while rapidly improving, are still nascent and continued careful evaluation in their applications to HTA is required. To ensure their responsible use and implementation, both developers and users of research incorporating these tools, should familiarize themselves with their current limitations, including the issues related to scientific validity, risk of bias, and consider equity and ethical implications. We also surveyed the current policy landscape and provide suggestions for HTA agencies on responsibly integrating generative AI into their workflows, emphasizing the importance of human oversight and the fast-evolving nature of these tools.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑